Why the ResMed (ASX:RMD) share price slumped even as profit jumped

A 14% increase in quarterly revenue wasn't enough to save the ResMed share price from profit takers.

| More on:
ResMed share price healthcare asx share price flat represented by doctor shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resmed CDI (ASX: RMD) tumbled even as management unveiled a double-digit increase in quarterly revenue and a bigger dividend.

But that wasn't enough to save the sleep-treatment device maker. The ResMed share price crashed by over 3% to $36.06 in early trade.

ResMed share price is worst performer

This makes it the worst performer on the S&P/ASX 200 Index (Index:^AXJO) at the time of writing.

That's even worse than ASX gold miners, which dominated the rest of the bottom ranks due to the weak gold price.

The Perseus Mining Limited (ASX: PRU) share price, Ramelius Resources Limited (ASX: RMS) and Northern Star Resources Ltd (ASX: NST) are right behind ResMed.

Profit and dividend growth

ResMed posted a 14% uplift in fourth quarter revenue compared to the same time last year to US$876.1 million.

This means its FY21 full year revenue will be 8% ahead of the previous year at US$3.2 billion.

The medtech giant also upped its quarterly dividend by 8% to US42 cents a share. Not that this matters much as investors don't buy the ResMed share price for its dividends.

Good news overshadowed by margin squeeze

But the news hasn't gone down well with investors as ResMed's margins are under pressure. Its non-GAAP gross margin fell 260 basis points (bps) to 57.3%. This dragged its full year margin down 70 bps to 59.1%.

ResMed said this is mainly due to an unfavourable product mix. Sales of lower-margin Sleep devices contributed more to group revenue this time round.

Further, lower average selling prices and foreign currency movements also weighed on margins. However, the foreign exchange "drag" bolstered ResMed's top line. So, I can only surmise that currency movements didn't have as big an impact on margins than the first two factors.

Profit takers hit the ResMed share price

Another reason why the ResMed share price came under pressure may have something to do with its 41% surge over the past year.

Shareholders sitting on strong returns would be looking for any excuse to lock in some profits. A margin squeeze is as good as any.

The fact that ResMed didn't offer much in the way of an outlook also made the profit-taking decision that much easier.

Outlook failed to inspire

"Looking ahead, we are confident in our ability to grow steadily through our fiscal year 2022 and to deliver for all our stakeholders," said ResMed's chief executive, Mick Farrell.

"We're driving accelerated adoption of digital health solutions in sleep apnea, COPD, and out-of-hospital care, accelerating our ResMed 2025 strategy."

After a big run-up in the shares, investors will need more than assurances of steady growth to keep pushing ResMed higher – at least for now.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »